홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

아포몰핀하이드로클로라이드

4H-Dibenzo[de,g]quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, hydrochloride (1:1), (6aR)-

HCID 9410
새 반응
인쇄
기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
314-19-2
표준 SMILES
CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3.Cl
InChIKey
SKYZYDSNJIOXRL-BTQNPOSSSA-N
분자식
C17H18ClNO2
평균 분자량
303.8 g/mol
단동위원소 질량
303.1026065

개요

See also: Apomorphine Hydrochloride (annotation moved to).

이름 및 식별자

우선 이름
4H-Dibenzo[de,g]quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, hydrochloride (1:1), (6aR)-
IUPAC
(6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol;hydrochloride
현지명
아포몰핀하이드로클로라이드
영어명
Apomorphine hydrochloride
분자식
C17H18ClNO2
분자량
303.78

이름 및 동의어

(-)-Apomorphine hydrochloride4H-Dibenzo(de,g)quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, hydrochloride (1:1), (6aR)-4H-Dibenzo[de,g]quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, hydrochloride (1:1), (6aR)-RefChem:527368314-19-2(R)-(-)-Apomorphine hydrochlorideApomorphine chlorideApomorphinium chlorideApomorphine hydrochloride anhydrous(-)-Apomorphine (hydrochloride)9K13MD7A0DApomorphine.HCl
이름 더 보기
아포몰핀하이드로클로라이드APOMORPHINE HCLAPL-130277(?)-Apomorphine(r)-idUPRIMATAK251)KW-6500R(–)-APONSC 11442APL130277
R-(-)-Apomorphine hydrochlorideApomorphine SLBritajectNSC-11442Apomorphin hydrochloridpomorphini hydrochloridumApomorphinum hydrochloricum(6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol;hydrochloride

물성

구조 계산 물성

극성 표면적
43.7 Ų
수소 결합 공여자 수
3
수소 결합 수용자 수
3
회전 가능 결합 수
0
무거운 원자 수
21
형식 전하
0
복잡도
374

실험 및 물리화학적 성질

Collision Cross Section161.7 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

물리화학적 성질

녹는점
250 ℃ · >250℃
저장 조건
Store at RT
용해도
1.08 mg/mL · ≥1.08 mg/mL in EtOH with ultrasonic; ≥12.9 mg/mL in DMSO; ≥5.12 mg/mL in H2O
물리적 상태
고체
EPA
Apomorphine hydrochloride (314-19-2)

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

유해성 정보

Other Safety InformationIMAP assessments - 4H-Dibenzo[de,g]quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, hydrochloride, (R)-: Environment tier I assessment

안전 데이터

tsca
TSCA listed
ridadr
3249
독성
mmo-sat 20 mg/plate MUREAV 137,17,84
포장분류
III
위험 등급
6.1(b)

화학 및 산업

용도 및 제조

General Manufacturing Information4H-Dibenzo[de,g]quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, hydrochloride (1:1), (6aR)-: INACTIVE
응용 분야 · 2건

용도Emetic.

일반 설명Apomorphine hydrochloride,(6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolone-10,11-diol hydrochloride (Apokyn), is awhite or off-white powder or crystal soluble in hot water(pKa=8.92). Apormorphine is an aporphine alkaloid of thebenzoquinoline class. Oral apomorphine is poorly absorbedand has a bioavailability of less than 4%. Upon subcutaneousadministration, apomorphine is completely absorbed. Within10 to 20 minutes, the maximum concentration of the drug isdistributed from the blood plasma to the CSF. Other potentialroutes of administration include continuous subcutaneous infusion,intravenous infusion, intranasal spray application,sublingual, and rectal administration.23 The agent is highlylipophilic in nature, allowing for rapid diffusion across theBBB after injection. Apomorphine has a short plasma halflife;however, clinical effects may last from 60 to 90 minutes.Apomorphine displays a significant degree of interpatientvariability in its pharmacokinetic profile. Studies of bothintravenous and subcutaneous injection routes found this variation was not attributable to body weight, age, gender,and duration of PD or L-DOPA dose/duration alone.Apomorphine is extensively metabolized. Hypothesizedroutes include sulfation, N-demethylation, glucuronidation,and oxidation. Subcutaneous injections of apomorphine arerenally and hepatically cleared, with the majority appearingto be renally cleared. Dosage adjustments are needed in bothliver and renal impairment. The activity of apomorphine isbelieved to be caused by stimulation of postsynaptic D1- andD2-type receptors within the caudate/putamen in the brain.Apomorphine is indicated for the acute, intermittent treatmentof hypomobility, “off” episodes (“end-of-dose wearingoff” and unpredictable on/off episodes) associated with advancedPD.

상·하류 제품 정보

상류 원료

인산

관련 반응

5건
반응 기록 만들기
HRID 520276 반응식
HRID 520276반응물로
HRID 520277 반응식
HRID 520277반응물로
HRID 1585445 반응식
HRID 1585445반응물로
HRID 2167017 반응식
HRID 2167017반응물로
HRID 2167018 반응식
HRID 2167018반응물로

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트

데이터베이스 식별자

CAS
314-19-2
PubChem CID
9410
DTXSID
DTXSID5040598
UNII
9K13MD7A0D
모르핀